Back to top
more

Apellis Pharmaceuticals (APLS)

(Real Time Quote from BATS)

$38.80 USD

38.80
874,847

+1.41 (3.77%)

Updated Jul 25, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug

by Zacks Equity Research

The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.

Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why

by Zacks Equity Research

Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.

Apellis (APLS), Sobi Get EU Nod for Rare Blood Disorder Drug

by Zacks Equity Research

The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.

Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates

by Zacks Equity Research

Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -31.79% and 143.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)

by Zacks Equity Research

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug

by Zacks Equity Research

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

    Apellis (APLS) Down on Mixed Data From Studies on GA Candidate

    by Zacks Equity Research

    Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.

    Apellis Pharmaceuticals, Inc. (APLS) Down 6.8% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    AstraZeneca (AZN) Stops Phase III Study on Ultomiris for ALS

    by Zacks Equity Research

    AstraZeneca (AZN) stops the phase III CHAMPION-ALS study on Ultomiris for treating adults with amyotrophic lateral sclerosis, following a recommendation from the Independent Data Monitoring Committee.

    Is the Options Market Predicting a Spike in Apellis (APLS) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Apellis (APLS) stock based on the movements in the options market lately.

    Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates

    by Zacks Equity Research

    Apellis (APLS) reports a wider-than-expected loss for the second quarter of 2021. Revenues too miss expectations.

    Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -60.00% and -72.43%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Why Apellis (APLS) Might Surprise This Earnings Season

    by Zacks Equity Research

    Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Apellis (APLS) Up on Tie-up With Beam for Novel Therapies

    by Zacks Equity Research

    Apellis (APLS) signs a collaboration deal with Beam Therapeutics to develop new treatments for complement-driven diseases. Shares rise.

    Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study

    by Zacks Equity Research

    Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.

    Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug

    by Zacks Equity Research

    Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.

    Is the Options Market Predicting a Spike in Apellis (APLS) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Apellis (APLS) stock based on the movements in the options market lately.

    Company News for May 18, 2021

    by Zacks Equity Research

    Companies In The News Are: HOME, MPC, UAL, APLS

    Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod

    by Zacks Equity Research

    The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.

    Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus

    by Zacks Equity Research

    Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.

    Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -37.28% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's Why

    by Zacks Equity Research

    Apellis Pharmaceuticals, Inc. (APLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.